Luca Pierelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3216609/publications.pdf

Version: 2024-02-01

94433 123424 4,743 179 37 61 citations h-index g-index papers 180 180 180 6223 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	CAR-T cells: the long and winding road to solid tumors. Cell Death and Disease, 2018, 9, 282.	6.3	312
2	Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biological Procedures Online, 2001, 3, 19-25.	2.9	280
3	Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood, 2006, 108, 218-227.	1.4	226
4	Expression of CD133-1 and CD133-2 in ovarian cancer. International Journal of Gynecological Cancer, 2008, 18, 506-514.	2.5	195
5	Cells with Characteristics of Cancer Stem/Progenitor Cells Express the CD133 Antigen in Human Endometrial Tumors. Clinical Cancer Research, 2009, 15, 4299-4311.	7.0	153
6	Role for granulocyte colony–stimulating factor in the generation of human T regulatory type 1 cells. Blood, 2002, 100, 2562-2571.	1.4	142
7	Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sites. Cancer Chemotherapy and Pharmacology, 1991, 28, 255-258.	2.3	120
8	Granulocyte colonyâ€stimulating factor promotes the generation of regulatory DC through induction of ILâ€10 and IFNâ€Î±. European Journal of Immunology, 2004, 34, 1291-1302.	2.9	120
9	Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sanguinis, 2014, 106, 197-208.	1.5	86
10	A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective singleâ€blind randomized controlled trial. Transfusion, 2015, 55, 1644-1654.	1.6	85
11	Targeting of macrophage galactoseâ€type <scp>C</scp> â€type lectin (<scp>MGL</scp>) induces <scp>DC</scp> signaling and activation. European Journal of Immunology, 2012, 42, 936-945.	2.9	84
12	Erythropoietin Addition to Granulocyte Colony-Stimulating Factor Abrogates Life-Threatening Neutropenia and Increases Peripheral-Blood Progenitor-Cell Mobilization After Epirubicin, Paclitaxel, and Cisplatin Combination Chemotherapy: Results of a Randomized Comparison. Journal of Clinical Oncology, 1999, 17, 1288-1288.	1.6	77
13	A human umbilical cord stem cell rescue therapy in a murine model of toxic liver injury. Digestive and Liver Disease, 2004, 36, 603-613.	0.9	74
14	A prospective, active haemovigilance study with combined cohort analysis of 19Â175 transfusions of platelet components prepared with amotosalen– <scp>UVA</scp> photochemical treatment. Vox Sanguinis, 2015, 109, 343-352.	1.5	73
15	CD105 (Endoglin) Expression on Hematopoietic Stem/Progenitor Cells. Leukemia and Lymphoma, 2001, 42, 1195-1206.	1.3	69
16	Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants. British Journal of Haematology, 2000, 108, 105-115.	2.5	68
17	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
18	Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells. Journal of Translational Medicine, 2014, 12, 28.	4.4	64

#	Article	IF	Citations
19	Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood, 1994, 84, 3532-3539.	1.4	62
20	Extracorporeal photopheresis for the treatment of acute and chronic graftâ€versusâ€host disease in adults and children: best practice recommendations from an <scp>I</scp> talian <scp>S</scp> ociety of <scp>H</scp> emapheresis and <scp>C</scp> ell <scp>M</scp> anipulation (<scp>SIdEM</scp>) and <scp>I</scp> roup for <scp>B</scp> one <scp>M</scp> arrow	1.6	59
21	<scp>T</scp> ransplantation (<scp>GITMO</scp>) consensus process. Transfusion, 2013, 53, 2340-2352. Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-β1 is a cell cycle–independent effect and influences their hematopoietic potential. Blood, 2000, 95, 3001-3009.	1.4	58
22	Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors. British Journal of Haematology, 1991, 79, 562-566.	2.5	51
23	The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leukemia Research, 1992, 16, 497-503.	0.8	49
24	MGL Receptor and Immunity: When the Ligand Can Make the Difference. Journal of Immunology Research, 2015, 2015, 1-8.	2.2	49
25	Human cord blood CD133+ cells immunoselected by a clinical-grade apparatus differentiate in vitro into endothelial- and cardiomyocyte-like cells. Transfusion, 2007, 47, 280-289.	1.6	48
26	Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion, 2012, 52, 893-905.	1.6	48
27	International Forum on <scp>GMP</scp> â€grade human platelet lysate for cell propagation: summary. Vox Sanguinis, 2018, 113, 80-87.	1.5	45
28	Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. British Journal of Haematology, 1991, 79, 444-450.	2.5	43
29	CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/â° precursors. British Journal of Haematology, 2000, 108, 610-620.	2.5	43
30	Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells. Transfusion, 2004, 44, 1087-1097.	1.6	43
31	Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. International Journal of Infectious Diseases, 2021, 106, 338-347.	3.3	43
32	Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy, 2003, 5, 19-30.	0.7	42
33	Identification of a Novel Subpopulation of Human Cord Blood CD34â^'CD133â^'CD7â^'CD45+Lineageâ^'Cells Capable of Lymphoid/NK Cell Differentiation After In Vitro Exposure to IL-15. Journal of Immunology, 2003, 171, 2977-2988.	0.8	42
34	Transfected human dendritic cells to induce antitumor immunity. Gene Therapy, 2000, 7, 1458-1466.	4.5	41
35	Thymoglobulin, interferon- \hat{l}^3 and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. Journal of Translational Medicine, 2010, 8, 129.	4.4	41
36	Further investigations on the expression of HLA-DR, CD33 and CD13 surface antigens in purified bone marrow and peripheral blood CD34 \hat{A}_{\pm} haematopoietic progenitor cells. British Journal of Haematology, 1993, 84, 24-30.	2.5	39

#	Article	IF	CITATIONS
37	Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicentre retrospective study. British Journal of Haematology, 1994, 86, 70-75.	2.5	37
38	Expression of cyclin-dependent kinase inhibitor p15INK4B during normal and leukemic myeloid differentiation. Experimental Hematology, 2000, 28, 519-526.	0.4	37
39	Autologous stem cell transplantation: sequential production of hematopoietic cytokines underlying granulocyte recovery. Cancer Research, 1993, 53, 1297-303.	0.9	37
40	Reduction of allogeneic red blood cell usage during cardiac surgery by an integrated intra―and postoperative blood salvage strategy: results of a randomized comparison. Transfusion, 2013, 53, 790-797.	1.6	34
41	Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Experimental Hematology, 2000, 28, 612-625.	0.4	32
42	Accurate prediction of autologous stem cell apheresis yields using a double variable-dependent method assures systematic efficiency control of continuous flow collection procedures. Vox Sanguinis, 2006, 91, 126-134.	1.5	32
43	Potency testing of mesenchymal stromal cell growth expanded in human platelet lysate from different human tissues. Stem Cell Research and Therapy, 2016, 7, 122.	5.5	32
44	Effect of age on DNA binding of the ku protein in irradiated human peripheral blood mononuclear cells (PBMC). Experimental Gerontology, 1999, 34, 645-658.	2.8	30
45	Optimization of the isolation and expansion method of human mediastinal–adipose tissue derived mesenchymal stem cells with virally inactivated GMP-grade platelet lysate. Cytotechnology, 2015, 67, 165-174.	1.6	30
46	Immune reconstitution after autologous peripheral blood progenitor cell transplantation. Experimental Hematology, 2001, 29, 1503-1516.	0.4	28
47	Transforming growth factor- \hat{l}^21 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects. Leukemia, 2002, 16, 94-105.	7.2	28
48	Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology, 2016, 48, 1369-1378.	3.3	28
49	Culture of human cell lines by a pathogen-inactivated human platelet lysate. Cytotechnology, 2016, 68, 1185-1195.	1.6	28
50	Constitutive and Inducible Expression of the Epithelial Antigen MUC1 (CD227) in Human T Cells. Experimental Cell Research, 2002, 280, 107-118.	2.6	27
51	Functional, phenotypic and molecular characterization of cytokine low-responding circulating CD34+ haemopoietic progenitors. British Journal of Haematology, 1998, 102, 1139-1150.	2.5	24
52	Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy, 2012, 14, 841-850.	0.7	24
53	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. Bone Marrow Transplantation, 2018, 53, 422-430.	2.4	24
54	Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications. Clinical Cancer Research, 2003, 9, 195-200.	7.0	24

#	Article	IF	Citations
55	Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer. European Journal of Cancer, 1993, 29, 1518-1522.	2.8	22
56	In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue. British Journal of Cancer, 1998, 78, 1024-1029.	6.4	21
57	Survival and Cell Cycle Control in Early Hematopoiesis: Role of Bcl-2, and the Cyclin Dependent Kinase Inhibitors P27 and P21. Leukemia and Lymphoma, 2002, 43, 51-57.	1.3	21
58	A Novel Route of Transplantation of Human Cord Blood Stem Cells in Preimmune Fetal Sheep: The Intracelomic Cavity. Stem Cells, 2003, 21, 638-646.	3.2	21
59	Retrospective analysis of HDFN due to ABO incompatibility in a single institution over 6 years. Transfusion Medicine, 2019, 29, 197-201.	1.1	21
60	Homogeneous expression of CXC chemokine receptor 4 (CXCR4) on G-CSF–mobilized peripheral blood CD34+ cells. Blood, 2000, 95, 4015-4016.	1.4	20
61	Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF- $\hat{1}^21$ is a cell cycle \hat{a} independent effect and influences their hematopoietic potential. Blood, 2000, 95, 3001-3009.	1.4	20
62	Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunology, Immunotherapy, 2001, 49, 641-648.	4.2	19
63	Transforming growth factor \hat{l}^21 causes transcriptional activation of CD34 and preserves haematopoietic stem/progenitor cell activity. British Journal of Haematology, 2002, 118, 627-637.	2.5	19
64	Regulated expression of MUC1 epithelial antigen in erythropoiesis. British Journal of Haematology, 2003, 120, 344-352.	2.5	19
65	Expansion of granulocyte colony–stimulating factor/chemotherapy–mobilized CD34+ hematopoietic progenitors. Experimental Hematology, 1999, 27, 416-424.	0.4	18
66	Stress, burnout, and job satisfaction in 470 health professionals in 98 apheresis units in <scp>I</scp> taly: A SIdEM collaborative study. Journal of Clinical Apheresis, 2015, 30, 297-304.	1.3	18
67	Evaluation of a Novel Automated Protocol for the Collection of Peripheral Blood Stem Cells Mobilized with Chemotherapy or Chemotherapy Plus G-CSF Using the Fresenius AS104 Cell Separator. Stem Cells and Development, 1993, 2, 145-153.	1.0	17
68	High-dose Chemotherapy with Autologous Peripheral Stem Cell Support in Advanced Ovarian Cancer. Annals of Medicine, 1995, 27, 133-138.	3.8	17
69	Generation of multinuclear tartrateâ€resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34 + progenitors. British Journal of Haematology, 1997, 96, 64-69.	2.5	17
70	T-cell apoptosis induced by granulocyte colony-stimulating factor is associated with retinoblastoma protein phosphorylation and reduced expression of cyclin-dependent kinase inhibitors. Experimental Hematology, 2001, 29, 401-415.	0.4	17
71	The Intracoelomic Route: A New Approach for in utero Human Cord Blood Stem Cell Transplantation. Fetal Diagnosis and Therapy, 2004, 19, 13-22.	1.4	17
72	Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. European Journal of Cancer, 1995, 31, 1987-1992.	2.8	16

#	Article	lF	CITATIONS
73	The combination of erythropoietin and granulocyte colonyâ€stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. British Journal of Haematology, 1996, 92, 287-294.	2.5	16
74	High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration. British Journal of Cancer, 1997, 75, 1205-1212.	6.4	16
75	Evaluation of Two Different Protocols for Peripheral Blood Stem Cell Collection with the Fresenius AS 104 Blood Cell Separator. Vox Sanguinis, 1997, 73, 230-236.	1.5	16
76	Autologous stem cell transplantation: evaluation of erythropoietic reconstitution by highly fluorescent reticulocyte counts, erythropoietin, soluble transferrin receptors, ferritin, TIBC and iron dosages. British Journal of Haematology, 1997, 96, 762-775.	2.5	16
77	High cyclin-dependent kinase inhibitors in Bcl-2 and Bcl-xL -expressing CD34+ -proliferating haematopoietic progenitors. British Journal of Haematology, 2000, 110, 654-662.	2.5	16
78	The Potential of GMP-Compliant Platelet Lysate to Induce a Permissive State for Cardiovascular Transdifferentiation in Human Mediastinal Adipose Tissue-Derived Mesenchymal Stem Cells. BioMed Research International, 2015, 2015, 1-10.	1.9	16
79	Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-beta1 is a cell cycle-independent effect and influences their hematopoietic potential. Blood, 2000, 95, 3001-9.	1.4	16
80	Effects of natural beta-interferon and recombinant alpha-2B-interferon on proliferation, glucocorticoid receptor content, and antigen expression in cultured HL-60 cells. Cancer, 1990, 65, 920-925.	4.1	15
81	Large Volume Leukapheresis for Collecting Hemopoietic Progenitors: Role of CD 34+ Precount in Predicting Successful Collection. International Journal of Artificial Organs, 1999, 22, 334-341.	1.4	15
82	A new standardized clinicalâ€grade protocol for banking human umbilical cord tissue cells. Transfusion, 2015, 55, 2864-2873.	1.6	15
83	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. International Journal of Molecular Sciences, 2019, 20, 1903.	4.1	15
84	High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transplantation, 2001, 27, 1017-1025.	2.4	14
85	Poor mobilizer: A retrospective study on proven and predicted incidence according to GITMO criteria. Transfusion and Apheresis Science, 2012, 47, 217-221.	1.0	14
86	GMP-grade platelet lysate enhances proliferation and migration of tenon fibroblasts. Frontiers in Bioscience - Elite, 2016, 8, 84-99.	1.8	14
87	Role of DNA-dependent protein kinase in recognition of radiation-induced DNA damage in human peripheral blood mononuclear cells. International Immunology, 2001, 13, 791-797.	4.0	13
88	Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transplantation, 2002, 30, 571-578.	2.4	13
89	Human Sinusoidal Subendothelial Cells Regulate Homing and Invasion of Circulating Metastatic Prostate Cancer Cells to Bone Marrow. Cancers, 2019, 11, 763.	3.7	13
90	Autologous bone marrow processing for autotransplantation using an automated cell processor and a semiautomated procedure. Bone Marrow Transplantation, 1991, 7, 355-61.	2.4	13

#	Article	IF	Citations
91	In vitro and in vivo effects of recombinant human erythropoietin plus recombinant human G-CSF on human haemopoietic progenitor cells. Bone Marrow Transplantation, 1994, 14, 23-30.	2.4	13
92	Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. American Journal of Hematology, 1994, 46, 18-23.	4.1	12
93	Patterns of recovery phase infection after autologous blood progenitor cell transplantation in patients with malignancies. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 552-556.	2.9	12
94	The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. Transfusion, 2001, 41, 1577-1585.	1.6	12
95	Transplantation of Autologous Peripheral Blood Progenitor Cells: Impact of CD34-Cell Selection on Immunological Reconstitution. Leukemia and Lymphoma, 2001, 42, 1207-1220.	1.3	12
96	Cell Cycle Regulation in Human Hematopoietic Stem Cells: From Isolation to Activation. Leukemia and Lymphoma, 2002, 43, 493-501.	1.3	12
97	Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells. BMC Immunology, 2009, 10, 46.	2.2	12
98	A policy for the disposal of autologous hematopoietic progenitor cells: report from an <scp>I</scp> talian consensus panel. Transfusion, 2014, 54, 2353-2360.	1.6	12
99	Evaluation of haemoglobin, haematocrit, haemolysis, residual protein content and leucocytes in 345 red blood cell concentrates used for the treatment of patients with \hat{l}^2 -thalassaemia. Blood Transfusion, 2012, 10, 39-44.	0.4	12
100	Stem cells in gynecology and obstetrics. Panminerva Medica, 2004, 46, 49-59.	0.8	12
101	Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF. Transfusion, 2001, 41, 674-680.	1.6	11
102	International Forum on GMPâ€grade human platelet lysate for cell propagation. Vox Sanguinis, 2018, 113, e1-e25.	1.5	11
103	The fusion protein MEN 11303 (granulocyte-macrophage colony stimulating factor/erythropoietin) acts as a potent inducer of erythropoiesis. Experimental Hematology, 2000, 28, 490-498.	0.4	10
104	A new blood donation strategy: Automated blood collection (ABC). International Journal of Artificial Organs, 2001, 24, 173-177.	1.4	10
105	Hepatitis B virus blood screening: impact of nucleic amplification technology testing implementation on identifying hepatitis B surface antigen nonâ€reactive window period and chronic infections. Vox Sanguinis, 2009, 96, 292-297.	1.5	10
106	The angiogenic properties of human adipose-derived stem cells (HASCs) are modulated by the High mobility group box protein 1 (HMGB1). International Journal of Cardiology, 2017, 249, 349-356.	1.7	10
107	Vox Sanguinis International Forum on application of fetal blood grouping: summary. Vox Sanguinis, 2018, 113, 198-201.	1.5	10
108	Indicative morphological myelodysplastic alterations of bone marrow in overt AIDS. Haematologica, 1990, 75, 327-33.	3. 5	10

#	Article	IF	CITATIONS
109	Characterization of peripheral blood CD34+ progenitor cells mobilized with chemotherapy and granulocyte colony-stimulating factor. Experimental Hematology, 1994, 22, 990-5.	0.4	10
110	Survival after PBSC Transplantation and Comparison of Engraftment Speed with Autologous and Allogeneic Marrow Transplantation: Results of a Multicenter Study. International Journal of Artificial Organs, 1993, 16, 45-50.	1.4	9
111	Emergency response of four transfusion centers during the last Chikungunya outbreak in Italy. Transfusion, 2018, 58, 3027-3030.	1.6	9
112	Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer. Bone Marrow Transplantation, 1994, 14, 907-12.	2.4	9
113	The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey. Transfusion and Apheresis Science. 2013. 49. 615-622.	1.0	8
114	Three missense mutations found in the KELgene lead to Kmodor KOred blood cell phenotypes. Transfusion, 2014, 54, 3216-3221.	1.6	8
115	Total nucleated cells as a sole predictor of distinct targets of hematopoietic potential (CD34+ cells) in cord blood units: the results of a large series analysis in autologous cord blood units. Transfusion, 2014, 54, 1256-1262.	1.6	8
116	Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway. Human Immunology, 2016, 77, 1239-1247.	2.4	8
117	Biosimilar filgrastim (Zarzio $\sin \hat{A}^{\otimes}$ (sup) vs. lenograstim (Myelostim $\sup \hat{A}^{\otimes}$ (sup) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience. Leukemia and Lymphoma, 2016, 57, 489-492.	1.3	8
118	Vox Sanguinis International Forum on application of fetal blood grouping. Vox Sanguinis, 2018, 113, e26-e35.	1.5	8
119	Chemotherapy-based versus chemotherapy-free stem cell mobilization ($\hat{A}\pm$ plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. Bone Marrow Transplantation, 2021, 56, 1876-1887.	2.4	8
120	Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di) Tj ETQq0 0 0	rg <mark>đđ</mark> O/Ove	rločk 10 Tf 50
121	"Best practice†for extracorporeal photopheresis in acute and chronic graftâ€versusâ€host disease by Societa' Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers. Transfusion. 2018. 58. 217-222.	1.6	7
122	A New Method to Evaluate in vitro Myelotoxicity of Antitumour Agents in the First Steps of Drug Development. Basic and Clinical Pharmacology and Toxicology, 2001, 89, 231-236.	0.0	7
123	In vitro release and expansion of mesenchymal stem cells by a hyaluronic acid scaffold used in combination with bone marrow. Muscles, Ligaments and Tendons Journal, 2012, 2, 289-94.	0.3	7
124	Survey of current practice for monitoring and management of platelet refractoriness in Italy. Transfusion and Apheresis Science, 2012, 47, 271-276.	1.0	6
125	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. Cytotherapy, 2014, 16, 101-110.	0.7	6
126	Homogeneous expression of CXC chemokine receptor 4 (CXCR4) on G-CSF–mobilized peripheral blood CD34+ cells. Blood, 2000, 95, 4015-4016.	1.4	6

#	Article	IF	CITATIONS
127	Homogeneous expression of CXC chemokine receptor 4 (CXCR4) on G-CSF-mobilized peripheral blood CD34+ cells. Blood, 2000, 95, 4015-6.	1.4	6
128	Autolo ous blood stem cell transplantation in malignant lymphomas: An itavian cooperative study. International Journal of Cell Cloning, 1992, 10, 132-134.	1.6	5
129	Growth Factor Administration Following Autologous Peripheral Blood Progenitor Cell Transplantation. Leukemia and Lymphoma, 1997, 27, 65-75.	1.3	5
130	Autologous Stem Cell Transplantation: Exogenous Granulocyte Colony-Stimulating Factor or Granulocyte-Macrophage Colony-Stimulating Factor Modulate the Endogenous Cytokine Levels. Blood, 1997, 89, 2615-2617.	1.4	5
131	Purified unfractionated G SF/chemotherapy mobilized CD34 + peripheral blood progenitors and not bone marrow CD34 + progenitors undergo selective erythroid differentiation in liquid culture in the presence of erythropoietin and stem cell factor. British Journal of Haematology, 1997, 96, 55-63.	2.5	5
132	Evaluation of a new protocol for peripheral blood stem cell collection with the Fresenius AS 104 cell separator. Journal of Clinical Apheresis, 1997, 12, 82-86.	1.3	5
133	Cytokines alone for PBPC collection in patients with advanced gynaecological malignancies: G-CSF vs G-CSF plus EPO. Bone Marrow Transplantation, 2004, 34, 743-744.	2.4	5
134	Evaluation of the analytical performances of a portable, 18-parameter hemometric system using capillary blood samples for blood donor enrolment. Vox Sanguinis, 2010, 98, 145-150.	1.5	5
135	Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use. Vox Sanguinis, 2017, 112, e48-e68.	1.5	5
136	Large volume leukapheresis for collecting hemopoietic progenitors: role of CD 34+ precount in predicting successful collection. International Journal of Artificial Organs, 1999, 22, 334-41.	1.4	5
137	Five-year Experience in PBSC Collection: Results of the Catholic University of Rome. International Journal of Artificial Organs, 1993, 16, 39-44.	1.4	4
138	Central venous catheter insertion in peripheral blood hematopoietic stem cell sibling donors: The SIdEM (Italian Society of Hemapheresis and Cell Manipulation) point of view. Transfusion and Apheresis Science, 2014, 50, 200-206.	1.0	4
139	Lenograstim 5 $\hat{A}\mu g/kg$ is not superior to biosimilar filgrastim 10 $\hat{A}\mu g/kg$ in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study. Transfusion, 2018, 58, 1143-1148.	1.6	4
140	Autologous Blood Stem Cell Transplantation in Malignant Lymphomas: An Italian Cooperative Study. Leukemia and Lymphoma, 1992, 7, 11-16.	1.3	3
141	Fetal Tissue Collection from Spontaneous Abortions: A Report from a Single Centre. Fetal Diagnosis and Therapy, 1994, 9, 204-208.	1.4	3
142	Bisdioxopiperazine, (+)-1,2-Bis(3,5-Dioxopiperazinyl-1-yl)propane (ICRF 187), Enhances the Antiproliferative Effect of Cisplatin on Human Ovarian Cancer Cells. Gynecologic Oncology, 1995, 57, 16-22.	1.4	3
143	The Application of Two Different Blood Cell Separators to Harvest CD34+ Cells in Patients Suffering from Non Hodgkin's Lymphoma. International Journal of Artificial Organs, 1999, 22, 583-588.	1.4	3
144	Enhanced Susceptibility to Apoptosis in T Cells Recovering after Autologous Peripheral Blood Progenitor Cell Transplantation: Reversal by Interleukin-15. Cytokines, Cellular & Molecular Therapy, 2000, 6, 189-198.	0.3	3

#	Article	IF	CITATIONS
145	Flow cytometric analysis of human hemopoietic progenitor differentiation by assessing cell division rate and phenotypic profile. Methods in Cell Biology, 2001, 64, 153-170.	1.1	3
146	Surfaces of antique marble sculptures in the Uffizi Gallery: reflection of history and image. Surface Engineering, 2005, 21, 378-384.	2.2	3
147	Integrated strategies for allogeneic blood saving in major elective surgery. Transfusion and Apheresis Science, 2011, 45, 281-285.	1.0	3
148	Counting of leukocytes in samples from G SF mobilized donors, leukapheresis products, and cord blood: the performances of an analyzer with dedicated profiles. International Journal of Laboratory Hematology, 2012, 34, 154-163.	1.3	3
149	Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary. Vox Sanguinis, 2017, 112, 680-683.	1.5	3
150	Pain control and functional improvement in patients treated by autologous conditioned serum after failure of platelet rich plasma treatments in knee osteoarthritis. Transfusion Medicine, 2021, 31, 357-364.	1.1	3
151	Vox Sanguinis International forum on the selection and preparation of blood components for intrauterine transfusion. Vox Sanguinis, 2020, 115, e18-e38.	1.5	3
152	In Vitro Expansion of CD34+ Cells Mobilized with Chemotherapy and G-CSF. International Journal of Artificial Organs, 1993, 16, 89-95.	1.4	2
153	Erythroplateletapheresis: A New Strategy in the Global Apheresis Program. International Journal of Artificial Organs, 1998, 21, 17-19.	1.4	2
154	Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer. Annals of Oncology, 1999, 10, 1531-1532.	1.2	2
155	Carboplatin-based neoadjuvant treatment with peripheral blood stem cell and growth factor support in locally advanced cervical cancer patients with bulky metastatic lymph nodes. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 131, 236-238.	1.1	2
156	Autologous transplantation of peripheral blood progenitor cells mobilized by chemotherapy with or without G-CSF (filgrastim) in resistant lymphoproliferative diseases: enhanced hemopoietic recovery with filgrastim primed progenitors. Haematologica, 1993, 78, 383-8.	3.5	2
157	Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters. American Journal of Clinical Pathology, 2012, 138, 308-309.	0.7	1
158	Plerixafor (Mozobil) and other mobilizing agents. Transfusion and Apheresis Science, 2013, 48, 133-135.	1.0	1
159	Cytotoxic potential of interleukin-15 stimulated cytokine induced killer (CIK) against epithelial cancer cell lines. Cytotherapy, 2014, 16, S23.	0.7	1
160	The Potential Role of Quorum Sensing in Clonal Growth and Subsequent Expansion of Bone Marrow Stromal Cell Strains in Culture. Stem Cells International, 2019, 2019, 1-10.	2.5	1
161	Two new RHD alleles with deletions spanning multiple exons. Transfusion, 2021, 61, 682-686.	1.6	1
162	International Forum on Transfusion Practices in Haematopoietic Stem ell Transplantation: Summary. Vox Sanguinis, 2021, 116, 609-612.	1.5	1

#	Article	IF	Citations
163	Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood, 1994, 84, 3532-3539.	1.4	1
164	Survival after PBSC transplantation and comparison of engraftment speed with autologous and allogeneic marrow transplantation: results of a multicenter study. International Journal of Artificial Organs, 1993, 16 Suppl 5, 45-50.	1.4	1
165	Predictors of cord blood unit cell content in a volume unrestricted large series collections: a chance for a fast and cheap multiparameter selection model. Stem Cell Research and Therapy, 2022, 13, .	5 . 5	1
166	Autologous Blood Stem Cell Collection after Chemotherapy in Patients with Sensitive and Refractory Malignancies: A Multicenter Retrospective Study. International Journal of Artificial Organs, 1993, 16, 19-24.	1.4	0
167	Perturbation of lymphocyte mitochondrial function and imbalance between BCL-2 family members as molecular mechanisms for g-csf-induced immune dysfunction. Experimental Hematology, 2000, 28, 112.	0.4	0
168	Stem Cell Collection using the Dideco Excel Continuous Flow Blood Cell Separator: Parameters for Optimal Stem Cell Collection Timing. International Journal of Artificial Organs, 2000, 23, 703-709.	1.4	0
169	Evaluation of the human haematopoietic stem cell potential in liver regeneration: Analysis of homing and differentiation patterns in a nod/scid mouse model. Journal of Hepatology, 2003, 38, 80-81.	3.7	0
170	A New Method to Evaluate in vitro Myelotoxicity of Antitumour Agents in the First Steps of Drug Development. Basic and Clinical Pharmacology and Toxicology, 2008, 89, 231-236.	0.0	0
171	The application of multiparameter reference intervals for preâ€donation capillary blood counts: the experience of a single institution. Transfusion Medicine, 2011, 21, 344-348.	1.1	0
172	Welcome to the 2nd International Joint Meeting ESFH-SIdEM May 19–22, Palazzo dei Congressi, Florence, Italy. Transfusion and Apheresis Science, 2013, 49, 374-375.	1.0	0
173	Two novel <i>RHD</i> alleles encoding truncated, nonfunctional D polypeptides. Transfusion, 2018, 58, 2082-2083.	1.6	0
174	A proposal for sectorial organizing and quality standards in therapeutic apheresis: The therapeutic apheresis unit (TAU) standards. Journal of Clinical Apheresis, 2019, 34, 513-516.	1.3	0
175	International Forum on Transfusion Practices in Haematopoietic Stem ell Transplantation: Responses. Vox Sanguinis, 2021, 116, e25-e43.	1.5	0
176	Interleukin (IL)-21 in Combination with IL-15 Induces the Differentiation of Human Umbilical Cord Blood CD34â^'Lineageâ^' Cells into Pseudomature Lytic NK Cells Blood, 2007, 110, 4031-4031.	1.4	0
177	Interleukin-21 Induces the Differentiation of Human Umbilical Cord Blood CD34. â^'lineageâ^' Cells Into Pseudomature Lytic NK Cells Blood, 2009, 114, 1476-1476.	1.4	0
178	Cell and Stem-Cell Therapies of Crohn's Disease and Complications. , 2010, , 131-141.		0
179	Autologous blood stem cell collection after chemotherapy in patients with sensitive and refractory malignancies: a multicenter retrospective study. International Journal of Artificial Organs, 1993, 16 Suppl 5, 19-24.	1.4	0